New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
05:38 EDTALKSAlkermes assumed with a Buy at Jefferies
Jefferies assumed coverage of Alkermes with a Buy rating and raised its price target for shares to $53 from $28. The firm believes Consta will not face generic competition until 2020.
News For ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
11:33 EDTALKSAlkermes label for Aristada better than expected, says Morgan Stanley
Subscribe for More Information
08:02 EDTALKSAlkermes approval brings 'key' near-term growth driver, says Leerink
Subscribe for More Information
07:02 EDTALKSAlkermes approval an incremental positive, says JPMorgan
Subscribe for More Information
06:44 EDTALKSAlkermes approval removes 'important overhang,' says Credit Suisse
Subscribe for More Information
October 5, 2015
18:24 EDTALKSAlkermes announces FDA approval of ARISTADA
Alkermes announced that the U.S. FDA has approved ARISTADA extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. Alkermes is preparing to launch ARISTADA immediately.
September 22, 2015
08:00 EDTALKSJefferies sees buying opportunities in select biotech names
Analysts at Jefferies say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). The Jefferies Biotechnology research team is led by Brian Abrahams, Eun Yang and Biren Amin.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use